Switzerland
· Delayed Price · Currency is CHF Newron Pharmaceuticals Company Description
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.
It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan.
The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication.
It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide.
The company was founded in 1999 and is headquartered in Bresso, Italy.
| Country | Italy |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Stefan Weber |
Contact Details
Address: Via Antonio Meucci 3 Bresso, 20091 Italy | |
| Phone | 39 02 610 3461 |
| Website | newron.com |
Stock Details
| Ticker Symbol | NWRN |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | IT0004147952 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Stefan Weber | Chief Executive Officer and Executive Director |
| Roberto Galli | Chief Financial Officer |
| Filippo Moriggia | Vice President of Operations |
| Dr. Ravi Anand M.D., Ph.D. | Chief Medical Officer |
| Laura Faravelli | Vice President of Business Development |